Drug Development in IPF
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib, need to be considered when selecting and developing new drug candidates. We discuss the challenges and opportunities in our new review in Drug Discovery Today. We probably don’t need to highlight the fact that despite […]
TherapeutAix turns two!
This September, TherapeutAix is two years old. Here, we look back on the past 12 months, and take a sneak peek into the future. Our Customers Our core mission is to help bring molecules with promise to life – and we are helping more customers in planning and navigating their drug discovery and development projects. […]
COVID-19 and Learning about Lung Fibrosis
Emerging understanding of the clinical course of COVID-19 may enable a better understanding of fibrosis in the lung. Future learnings may eventually be applicable to IPF and require new approaches to drug development. Reversing fibrosis and restoring lung function has been an aspiration for the treatment of patients with interstitial lung disease (ILD) but the […]
Frequently Asked Questions (FAQs)
Frequently Asked Questions (FAQs) How we work There are four members of the TherapeutAix team. Does this mean that I will end up paying more for your services than I would with an individual consultant? No. At TherapeutAix, we have overlapping and complementary expertise. This means that we can draw from our collective knowledge and […]
TherapeutAix to present at ELRIG Drug Discovery 2019 in Liverpool
Now in its 13th year, Drug Discovery 2019, ELRIG’s flagship conference, will take place at the ACC in Liverpool on the 5-6th November. The conference is one of the largest meetings of life science industry professionals in the UK. The focus of this year’s event is ‘A Look Back to the Future’ which will examine […]
One year round up – what we’ve been up to in our first year
The 1st September 2019 officially marks the one year anniversary of the launch of TherapeutAix – and what an exciting year it’s been! To celebrate the occasion, we’ve taken a look back at what the company has achieved so far. Company launch After months of preparation, we officially launched TherapeutAix on 1st September 2018 along […]
2018 Round Up – It’s a wrap
Since 2018 is quickly coming to an end, we look back at the past few months and reflect on all that we have achieved. The launch of the business is all wrapped up and now we look forward to what 2019 will bring. We would like to thank all of our clients and contacts for […]
Publications
Publications Extracellular Matrix Pharmacology Congress (June 2022) ECM-derived Biomarkers in Drug Discovery: Are they ready to deliver? Poster – Darcey Black. Drug discovery and development in idiopathic pulmonary fibrosis:challenges and opportunities (Drug Discovery Today, Sept 2020) A paper detailing the current treatments and clinical development landscape in IPF, as well as the new drugs in […]
Therapeutic Areas
Therapeutic Areas Collectively, the TherapeutAix team has a successful track record in the cardiovascular, inflammation, immunology, neuroscience, respiratory, pain, tissue repair and urology areas. Within this broad expertise, we have recently helped clients progress projects in fibrotic diseases, inflammatory and CNS indications, including large as well as rare/orphan and niche indications. Clients Our clients include […]